Annual Cash & Cash Equivalents
$23.63 M
+$6.52 M+38.12%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual cash & cash equivalents is $23.63 million, with the most recent change of +$6.52 million (+38.12%) on December 31, 2023.
- During the last 3 years, PLX annual cash & cash equivalents has risen by +$5.37 million (+29.40%).
- PLX annual cash & cash equivalents is now -72.65% below its all-time high of $86.40 million, reached on December 31, 2013.
Performance
PLX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$27.41 M
+$4.01 M+17.14%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly cash and cash equivalents is $27.41 million, with the most recent change of +$4.01 million (+17.14%) on September 30, 2024.
- Over the past year, PLX quarterly cash and cash equivalents has increased by +$7.00 million (+34.31%).
- PLX quarterly cash and cash equivalents is now -70.01% below its all-time high of $91.40 million, reached on September 30, 2013.
Performance
PLX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PLX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +38.1% | +34.3% |
| 3 y3 years | +29.4% | +34.3% |
| 5 y5 years | -37.5% | +34.3% |
PLX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -39.4% | +38.1% | -43.1% | +155.7% |
| 5 y | 5-year | -39.4% | +38.1% | -43.1% | +465.9% |
| alltime | all time | -72.7% | >+9999.0% | -70.0% | >+9999.0% |
Protalix BioTherapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $27.41 M(+17.1%) |
| Jun 2024 | - | $23.40 M(-14.0%) |
| Mar 2024 | - | $27.21 M(+15.1%) |
| Dec 2023 | $23.63 M(+38.1%) | $23.63 M(+15.8%) |
| Sep 2023 | - | $20.41 M(-57.6%) |
| Jun 2023 | - | $48.18 M(+45.9%) |
| Mar 2023 | - | $33.04 M(+93.1%) |
| Dec 2022 | $17.11 M(-56.1%) | $17.11 M(+59.6%) |
| Sep 2022 | - | $10.72 M(-14.2%) |
| Jun 2022 | - | $12.49 M(-26.0%) |
| Mar 2022 | - | $16.89 M(-56.7%) |
| Dec 2021 | $38.98 M(+113.4%) | $38.98 M(+266.3%) |
| Sep 2021 | - | $10.64 M(-68.6%) |
| Jun 2021 | - | $33.88 M(+70.9%) |
| Mar 2021 | - | $19.83 M(+8.6%) |
| Dec 2020 | $18.27 M(+2.7%) | $18.27 M(+35.0%) |
| Sep 2020 | - | $13.53 M(+179.4%) |
| Jun 2020 | - | $4.84 M(-65.8%) |
| Mar 2020 | - | $14.17 M(-20.4%) |
| Dec 2019 | $17.79 M(-52.9%) | $17.79 M(-17.0%) |
| Sep 2019 | - | $21.44 M(-14.6%) |
| Jun 2019 | - | $25.10 M(-17.3%) |
| Mar 2019 | - | $30.36 M(-19.7%) |
| Dec 2018 | $37.81 M(-26.1%) | $37.81 M(-9.7%) |
| Sep 2018 | - | $41.87 M(+47.8%) |
| Jun 2018 | - | $28.33 M(-31.4%) |
| Mar 2018 | - | $41.32 M(-19.2%) |
| Dec 2017 | $51.16 M(-19.1%) | $51.16 M(+52.8%) |
| Sep 2017 | - | $33.48 M(-3.0%) |
| Jun 2017 | - | $34.53 M(-28.1%) |
| Mar 2017 | - | $48.02 M(-24.1%) |
| Dec 2016 | $63.28 M(-17.1%) | $63.28 M(+23.3%) |
| Sep 2016 | - | $51.32 M(-6.1%) |
| Jun 2016 | - | $54.63 M(-18.1%) |
| Mar 2016 | - | $66.67 M(-12.7%) |
| Dec 2015 | $76.37 M(+39.5%) | $76.37 M(+123.0%) |
| Sep 2015 | - | $34.25 M(-20.8%) |
| Jun 2015 | - | $43.24 M(-9.8%) |
| Mar 2015 | - | $47.96 M(-12.4%) |
| Dec 2014 | $54.77 M(-36.6%) | $54.77 M(-9.2%) |
| Sep 2014 | - | $60.32 M(-15.2%) |
| Jun 2014 | - | $71.14 M(-8.4%) |
| Mar 2014 | - | $77.69 M(-10.1%) |
| Dec 2013 | $86.40 M(+66.0%) | $86.40 M(-5.5%) |
| Sep 2013 | - | $91.40 M(+175.9%) |
| Jun 2013 | - | $33.13 M(-20.9%) |
| Mar 2013 | - | $41.87 M(-19.5%) |
| Dec 2012 | $52.03 M(+92.7%) | $52.03 M(+3.6%) |
| Sep 2012 | - | $50.22 M(-15.3%) |
| Jun 2012 | - | $59.28 M(+30.0%) |
| Mar 2012 | - | $45.60 M(+68.9%) |
| Dec 2011 | $27.00 M | $27.00 M(-21.9%) |
| Sep 2011 | - | $34.56 M(-21.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2011 | - | $44.05 M(-12.3%) |
| Mar 2011 | - | $50.23 M(+39.9%) |
| Dec 2010 | $35.90 M(-55.8%) | $35.90 M(-19.1%) |
| Sep 2010 | - | $44.40 M(-19.2%) |
| Jun 2010 | - | $54.96 M(-20.8%) |
| Mar 2010 | - | $69.36 M(-14.6%) |
| Dec 2009 | $81.27 M(+90.8%) | $81.27 M(+259.4%) |
| Sep 2009 | - | $22.61 M(-22.4%) |
| Jun 2009 | - | $29.13 M(-16.6%) |
| Mar 2009 | - | $34.91 M(-18.0%) |
| Dec 2008 | $42.60 M(-31.1%) | $42.60 M(-7.5%) |
| Sep 2008 | - | $46.05 M(-13.7%) |
| Jun 2008 | - | $53.36 M(-7.7%) |
| Mar 2008 | - | $57.78 M(-6.5%) |
| Dec 2007 | $61.81 M(+302.0%) | $61.81 M(+202.4%) |
| Sep 2007 | - | $20.44 M(-9.1%) |
| Jun 2007 | - | $22.49 M(-9.7%) |
| Mar 2007 | - | $24.90 M(+61.9%) |
| Dec 2006 | $15.38 M(+224.4%) | $15.38 M(+1762.4%) |
| Sep 2006 | - | $825.70 K(-10.7%) |
| Jun 2006 | - | $924.90 K(-0.7%) |
| Mar 2006 | - | $931.70 K(-80.3%) |
| Dec 2005 | $4.74 M(+740.6%) | $4.74 M(+860.1%) |
| Sep 2005 | - | $493.80 K(-4.2%) |
| Jun 2005 | - | $515.20 K(-3.4%) |
| Mar 2005 | - | $533.20 K(-5.5%) |
| Dec 2004 | $564.00 K(+214.2%) | $564.00 K(-2.6%) |
| Sep 2004 | - | $579.10 K(-6.9%) |
| Jun 2004 | - | $622.10 K(+449.1%) |
| Mar 2004 | - | $113.30 K(-36.9%) |
| Dec 2003 | $179.50 K(-77.8%) | $179.50 K(-76.3%) |
| Sep 2003 | - | $756.10 K(-2.6%) |
| Jun 2003 | - | $776.60 K(-5.2%) |
| Mar 2003 | - | $819.40 K(+1.5%) |
| Dec 2002 | $807.60 K(-11.8%) | $807.60 K(-1.9%) |
| Sep 2002 | - | $823.60 K(-1.6%) |
| Jun 2002 | - | $836.80 K(-3.0%) |
| Mar 2002 | - | $862.80 K(-5.8%) |
| Dec 2001 | $915.60 K(+134.3%) | $915.60 K(-1.8%) |
| Sep 2001 | - | $932.80 K(-1.4%) |
| Jun 2001 | - | $946.20 K(+181.4%) |
| Mar 2001 | - | $336.20 K(-13.9%) |
| Dec 2000 | $390.70 K(-4.1%) | $390.70 K(+2.8%) |
| Sep 2000 | - | $379.90 K(-12.1%) |
| Jun 2000 | - | $432.00 K(+15.0%) |
| Mar 2000 | - | $375.60 K(-7.8%) |
| Dec 1999 | $407.50 K(-68.4%) | $407.50 K(-68.0%) |
| Sep 1999 | - | $1.27 M(+28.9%) |
| Jun 1999 | - | $989.10 K(+31.0%) |
| Mar 1999 | - | $754.80 K |
| Dec 1998 | $1.29 M(+135.4%) | - |
| Dec 1997 | $547.90 K(-28.3%) | - |
| Dec 1996 | $764.00 K | - |
FAQ
- What is Protalix BioTherapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual cash & cash equivalents year-on-year change?
- What is Protalix BioTherapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly cash and cash equivalents year-on-year change?
What is Protalix BioTherapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PLX is $23.63 M
What is the all time high annual cash & cash equivalents for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual cash & cash equivalents is $86.40 M
What is Protalix BioTherapeutics annual cash & cash equivalents year-on-year change?
Over the past year, PLX annual cash & cash equivalents has changed by +$6.52 M (+38.12%)
What is Protalix BioTherapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PLX is $27.41 M
What is the all time high quarterly cash and cash equivalents for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly cash and cash equivalents is $91.40 M
What is Protalix BioTherapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, PLX quarterly cash and cash equivalents has changed by +$7.00 M (+34.31%)